Unusual Resistance Mechanisms in a Case of ROS1-Rearranged NSCLC: A Case Report

The unprecedented growth of the high-throughput next-generation sequencing has facilitated the identification of rare oncogene fusions such as ROS1 for NSCLC. ROS1 rearrangement has been observed in only 2% of cases of NSCLC and has been successfully targeted using various tyrosine kinase inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales: Batra, Ullas, Nathany, Shrinidhi, Sharma, Mansi, Mattoo, Sakshi, Jose, Joslia T., Mehta, Anurag
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889240/
https://www.ncbi.nlm.nih.gov/pubmed/35252896
http://dx.doi.org/10.1016/j.jtocrr.2022.100286
Descripción
Sumario:The unprecedented growth of the high-throughput next-generation sequencing has facilitated the identification of rare oncogene fusions such as ROS1 for NSCLC. ROS1 rearrangement has been observed in only 2% of cases of NSCLC and has been successfully targeted using various tyrosine kinase inhibitors including crizotinib. However, the on-target and off-target mechanisms of the resistance are still vague. Here, we report a case of a patient with ROS1 rearranged NSCLC presenting primary resistance to crizotinib.

Ejemplares similares